Thoughts on Metastatic Kidney Cancer
0 Views
administrator
07/10/23
Panelists Robert A. Figlin, MD; Toni K. Choueiri, MD; Michael R. Harrison, MD; Eric Jonasch, MD; and David I. Quinn, MBBS, PhD, provide insight on the need for a biomarker in metastatic kidney cancer as novel agents move into the frontline setting, as well as the importance of managing toxicity and maintaining quality of life.
-
Category
Show more
Facebook Comments
No comments found